Dennis H. Pedder

Array ( [id] => 10262769 [patent_doc_number] => 20150147766 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-05-28 [patent_title] => 'METHOD FOR DETERMINING DISEASE SEVERITY IN TAUOPATHY-RELATED NEURODEGENERATIVE DISORDERS' [patent_app_type] => utility [patent_app_number] => 14/403876 [patent_app_country] => US [patent_app_date] => 2013-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 11488 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14403876 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10233248 [patent_doc_number] => 20150118241 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-04-30 [patent_title] => 'LINGO-2 ANTAGONISTS FOR TREATMENT OF CONDITIONS INVOLVING MOTOR NEURONS' [patent_app_type] => utility [patent_app_number] => 14/401002 [patent_app_country] => US [patent_app_date] => 2013-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 35661 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 19 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14401002 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9463846 [patent_doc_number] => 20140128273 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-05-08 [patent_title] => 'Metabolic Syndrome and HPA Axis Biomarkers for Major Depressive Disorder' [patent_app_type] => utility [patent_app_number] => 13/892714 [patent_app_country] => US [patent_app_date] => 2013-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 8550 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13892714 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9004366 [patent_doc_number] => 20130225490 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-29 [patent_title] => 'Antibodies That Inhibit TSLP Activity' [patent_app_type] => utility [patent_app_number] => 13/887893 [patent_app_country] => US [patent_app_date] => 2013-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 21214 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13887893 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9191425 [patent_doc_number] => 20130330740 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-12-12 [patent_title] => 'NOVEL THERAPEUTIC AND DIAGNOSTIC PRODUCTS AND METHODS' [patent_app_type] => utility [patent_app_number] => 13/887156 [patent_app_country] => US [patent_app_date] => 2013-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16581 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13887156 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9147829 [patent_doc_number] => 20130302352 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-11-14 [patent_title] => 'Methods for the prevention and/or treatment of memory impairment' [patent_app_type] => utility [patent_app_number] => 13/867470 [patent_app_country] => US [patent_app_date] => 2013-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 48 [patent_figures_cnt] => 48 [patent_no_of_words] => 48762 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13867470 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9174359 [patent_doc_number] => 20130316343 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-11-28 [patent_title] => 'DELTA3, FTHMA-070, TANGO85, TANGO77, SPOIL, NEOKINE, TANGO129, AND INTEGRIN ALPHA SUBUNIT PROTEIN AND NUCLEIC ACID MOLECULES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 13/866501 [patent_app_country] => US [patent_app_date] => 2013-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 164389 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13866501 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10219813 [patent_doc_number] => 20150104806 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-04-16 [patent_title] => 'Parkinson\'s Disease Biomarker' [patent_app_type] => utility [patent_app_number] => 14/391372 [patent_app_country] => US [patent_app_date] => 2013-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 13790 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14391372 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10006807 [patent_doc_number] => 09050305 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-06-09 [patent_title] => 'Treatment for ischemic stroke' [patent_app_type] => utility [patent_app_number] => 13/853183 [patent_app_country] => US [patent_app_date] => 2013-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4704 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13853183 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12036547 [patent_doc_number] => 09814761 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-11-14 [patent_title] => 'Compositions, methods and assays comprising amylin or amlyin analogs for abeta-peptide mediated disorders' [patent_app_type] => utility [patent_app_number] => 14/388485 [patent_app_country] => US [patent_app_date] => 2013-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 37 [patent_no_of_words] => 45760 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14388485 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11751564 [patent_doc_number] => 09709573 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-07-18 [patent_title] => 'Citrullinated brain and neurological proteins as biomarkers of brain injury or neurodegeneration' [patent_app_type] => utility [patent_app_number] => 14/384848 [patent_app_country] => US [patent_app_date] => 2013-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 24 [patent_no_of_words] => 27873 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 188 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14384848 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9042297 [patent_doc_number] => 20130244935 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-09-19 [patent_title] => 'Methods of Treating Necrotizing Enterocolitis Using Heparin Binding Epidermal Growth Factor' [patent_app_type] => utility [patent_app_number] => 13/793940 [patent_app_country] => US [patent_app_date] => 2013-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 11882 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13793940 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8915951 [patent_doc_number] => 20130177576 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-07-11 [patent_title] => 'Compositions And Methods For The Treatment Of Neurologic And Psychiatric Conditions' [patent_app_type] => utility [patent_app_number] => 13/789617 [patent_app_country] => US [patent_app_date] => 2013-03-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 21773 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13789617 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9812004 [patent_doc_number] => 20150023949 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-01-22 [patent_title] => 'COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDER' [patent_app_type] => utility [patent_app_number] => 14/383450 [patent_app_country] => US [patent_app_date] => 2013-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 65118 [patent_no_of_claims] => 47 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14383450 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11845707 [patent_doc_number] => 09733258 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-08-15 [patent_title] => 'Biomarker for determining mitochondrial damage in friedreich\'s ataxia' [patent_app_type] => utility [patent_app_number] => 14/382367 [patent_app_country] => US [patent_app_date] => 2013-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 22 [patent_no_of_words] => 7562 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14382367 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9951149 [patent_doc_number] => 08999936 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-04-07 [patent_title] => 'Antibodies specific for soluble amyloid beta peptide protofibrils and uses thereof' [patent_app_type] => utility [patent_app_number] => 13/780643 [patent_app_country] => US [patent_app_date] => 2013-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 9 [patent_no_of_words] => 7693 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13780643 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9034281 [patent_doc_number] => 20130236919 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-09-12 [patent_title] => 'METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING MOOD DISORDERS' [patent_app_type] => utility [patent_app_number] => 13/778397 [patent_app_country] => US [patent_app_date] => 2013-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 32002 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13778397 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8928453 [patent_doc_number] => 20130184213 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-07-18 [patent_title] => 'Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders' [patent_app_type] => utility [patent_app_number] => 13/777149 [patent_app_country] => US [patent_app_date] => 2013-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 18442 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13777149 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9003098 [patent_doc_number] => 20130224223 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-29 [patent_title] => 'Compositions and Methods for Treating Neurological Disorders' [patent_app_type] => utility [patent_app_number] => 13/770904 [patent_app_country] => US [patent_app_date] => 2013-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 15862 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13770904 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13035401 [patent_doc_number] => 10039813 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-08-07 [patent_title] => Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness [patent_app_type] => utility [patent_app_number] => 14/377229 [patent_app_country] => US [patent_app_date] => 2013-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 52 [patent_no_of_words] => 17626 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 119 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14377229 [rel_patent_id] =>[rel_patent_doc_number] =>)